Medtronic Reports 14% Revenue Growth to $9.76 Billion, Net Income Increases to $1.47 Billion

Medtronic plc reported a significant increase in financial performance for the three months ended July 31, 2026, with net sales reaching $9.76 billion, a 14% increase from $8.58 billion in the same period last year. The company's net income attributable to Medtronic was $1.47 billion, or $1.14 per diluted share, compared to $1.04 billion, or $0.81 per diluted share, in the prior year. This growth was driven by strong performance across various business segments, particularly in the Cardiovascular and Neuroscience portfolios, which saw net sales increases of 20% and 10%, respectively.

The company experienced notable changes in its operational structure, including the completion of the initial public offering (IPO) for its Diabetes Business, MiniMed Group, Inc., on March 9, 2026. Medtronic retained a controlling interest in MiniMed, which is reflected in its consolidated financial statements. Additionally, Medtronic made strategic acquisitions, including Scientia Vascular and SPR Therapeutics, aimed at enhancing its product offerings in the Specialty Therapies and Neuromodulation divisions, respectively.

Operationally, Medtronic reported a total employee headcount of approximately 100,000 as of July 31, 2026. The company also noted an increase in cash provided by operating activities, which rose to $1.79 billion from $1.09 billion year-over-year. The increase in cash flow was attributed to higher sales and improved collection from customers. However, cash used in investing activities increased significantly to $1.62 billion, primarily due to acquisitions.

Looking ahead, Medtronic anticipates continued growth driven by the expansion of its product lines and geographic reach. The company is focused on enhancing its market share in key areas, including Electrophysiology Therapies and Interventional Cardiology. Medtronic's management remains cautious about potential macroeconomic challenges, including pricing pressures and regulatory changes, but is optimistic about the long-term outlook for its diverse portfolio of medical technologies.

In summary, Medtronic's latest financial results reflect a strong upward trajectory, bolstered by strategic acquisitions and a focus on innovation across its product lines. The company is well-positioned to navigate future challenges while continuing to deliver value to its shareholders and improve patient outcomes globally.